The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why some cancer patients benefit from immunotherapy while others do not. In a ...

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why ...

Cancer immunotherapy has transformed modern oncology by harnessing the body's own immune system to combat malignant disease. Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have produced ...

In a study published in the journal Biofunctional materials, researchers from the Wits Advanced Drug Delivery Platform (WADDP) Research Unit, Department of Pharmacy and Pharmacology, and the Division ...

Please provide your email address to receive an email when new articles are posted on . More than 7% of patients receiving immune checkpoint blockade therapy and antibiotics developed immune-related ...

Immune Checkpoint Blockade (ICB) has reshaped cancer care and can deliver durable remission in malignancies such as melanoma and non-small cell lung cancer.

Vaxiion Therapeutics Announces Completion of Phase 1a Dose Escalation and Initiation of a Phase 1b Dose Expansion Study for Intralesional Administration of VAX014 in Combination with PD-1 Directed ...

A research team led by Professor Chen Peng from the College of Chemistry and Molecular Engineering at Peking University has developed a novel cancer immunotherapy strategy that forces tumors to expose ...